These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 33719499)

  • 1. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
    Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
    J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
    Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
    Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin directly improves diastolic function in human heart failure.
    Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
    Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
    J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
    Shi L; Zhu D; Wang S; Jiang A; Li F
    Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
    Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
    Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats.
    Daud E; Ertracht O; Bandel N; Moady G; Shehadeh M; Reuveni T; Atar S
    Cardiovasc Diabetol; 2021 Jul; 20(1):132. PubMed ID: 34215277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload.
    Nakao M; Shimizu I; Katsuumi G; Yoshida Y; Suda M; Hayashi Y; Ikegami R; Hsiao YT; Okuda S; Soga T; Minamino T
    Sci Rep; 2021 Sep; 11(1):18384. PubMed ID: 34526601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
    Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
    Krasnova M; Kulikov A; Okovityi S; Ivkin D; Karpov A; Kaschina E; Smirnov A
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1649-1658. PubMed ID: 32377771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
    Mustroph J; Wagemann O; Lücht CM; Trum M; Hammer KP; Sag CM; Lebek S; Tarnowski D; Reinders J; Perbellini F; Terracciano C; Schmid C; Schopka S; Hilker M; Zausig Y; Pabel S; Sossalla ST; Schweda F; Maier LS; Wagner S
    ESC Heart Fail; 2018 Aug; 5(4):642-648. PubMed ID: 30117720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.
    Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Garcia-Ropero A; Ishikawa K; Watanabe S; Picatoste B; Vargas-Delgado AP; Flores-Umanzor EJ; Sanz J; Fuster V; Badimon JJ
    JACC Cardiovasc Imaging; 2021 Feb; 14(2):393-407. PubMed ID: 33129742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy.
    Yerra VG; Batchu SN; Kabir G; Advani SL; Liu Y; Siddiqi FS; Connelly KA; Advani A
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):619-632. PubMed ID: 33886003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure.
    Nambu H; Takada S; Fukushima A; Matsumoto J; Kakutani N; Maekawa S; Shirakawa R; Nakano I; Furihata T; Katayama T; Yamanashi K; Obata Y; Saito A; Yokota T; Kinugawa S
    Eur J Pharmacol; 2020 Jan; 866():172810. PubMed ID: 31738936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental model of congestive heart failure induced by transverse aortic constriction in BALB/c mice.
    Tannu S; Allocco J; Yarde M; Wong P; Ma X
    J Pharmacol Toxicol Methods; 2020; 106():106935. PubMed ID: 33096237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin improves left ventricular diastolic function of db/db mice.
    Moellmann J; Klinkhammer BM; Droste P; Kappel B; Haj-Yehia E; Maxeiner S; Artati A; Adamski J; Boor P; Schütt K; Lopaschuk GD; Verma S; Marx N; Lehrke M
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165807. PubMed ID: 32353614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.